GRAIL, Inc. (NASDAQ:GRAL) Receives $90.17 Consensus PT from Analysts

Shares of GRAIL, Inc. (NASDAQ:GRAL) have received an average recommendation of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $82.00.

Several equities analysts have commented on GRAL shares. Morgan Stanley decreased their price target on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 24th. TD Cowen raised GRAIL from a “hold” rating to a “buy” rating and set a $65.00 price objective on the stock in a research report on Wednesday. Guggenheim increased their price objective on GRAIL from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Finally, Canaccord Genuity Group lowered their target price on GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a research note on Friday, February 20th.

Insider Activity

In other news, CFO Aaron Freidin sold 9,573 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $50.17, for a total transaction of $480,277.41. Following the completion of the transaction, the chief financial officer directly owned 309,622 shares of the company’s stock, valued at approximately $15,533,735.74. The trade was a 3.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, President Joshua J. Ofman sold 17,002 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $50.16, for a total transaction of $852,820.32. Following the completion of the sale, the president directly owned 436,508 shares in the company, valued at approximately $21,895,241.28. This trade represents a 3.75% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 79,294 shares of company stock worth $3,955,224. 1.85% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On GRAIL

Institutional investors have recently modified their holdings of the company. Farallon Capital Management LLC lifted its holdings in shares of GRAIL by 73.7% in the 4th quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock valued at $200,510,000 after purchasing an additional 993,684 shares during the last quarter. Baker BROS. Advisors LP lifted its stake in GRAIL by 27.9% in the fourth quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock valued at $178,484,000 after buying an additional 455,208 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of GRAIL by 9.0% in the fourth quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock valued at $169,535,000 after acquiring an additional 163,790 shares during the period. State Street Corp grew its position in shares of GRAIL by 38.8% during the fourth quarter. State Street Corp now owns 1,827,523 shares of the company’s stock worth $156,418,000 after acquiring an additional 510,546 shares during the last quarter. Finally, Morgan Stanley increased its holdings in shares of GRAIL by 63.8% in the 4th quarter. Morgan Stanley now owns 1,511,687 shares of the company’s stock valued at $129,385,000 after acquiring an additional 588,647 shares during the period.

GRAIL Price Performance

NASDAQ GRAL opened at $48.41 on Monday. The company has a market cap of $1.99 billion, a P/E ratio of -4.33 and a beta of 5.18. The stock has a 50-day moving average of $81.65 and a two-hundred day moving average of $78.30. GRAIL has a 1-year low of $20.44 and a 1-year high of $118.84.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($2.44) EPS for the quarter, beating the consensus estimate of ($3.33) by $0.89. The business had revenue of $43.60 million during the quarter, compared to analyst estimates of $43.33 million. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.11%. On average, analysts anticipate that GRAIL will post -15.15 EPS for the current fiscal year.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.